http://goldbamboo.com/ Sulfisoxazole Ophthalmic News from GoldBamboo.com en-us © 2005, Gold Bamboo LLC, All Rights Reserved http://goldbamboo.com/news-a221855.html Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company had begun treating patients in its LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TreatmEnt) pivotal clinical trial program of LX211, the company's next-generation calcineurin inhibitor. [click link for full article] Wed, 21 Feb 2007 08:00 EST http://goldbamboo.com/news-a220908.html Research on the genetic basis of eye diseases is enabling rapid progress in the diagnosis and treatment of these conditions, according to a series of articles on ophthalmic genetics in the February issue of Archives of Ophthalmology, one of the JAMA/Archives journals. [click link for full article] Thu, 15 Feb 2007 04:00 EST http://goldbamboo.com/news-a216115.html Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceuticals company, announced today that it has reached an exclusive licensing agreement with Laboratoires Thea of France for the U.S. rights to develop and market a topical ophthalmic gel containing ganciclovir for the treatment of certain viral and superficial eye infections. [click link for full article] Thu, 18 Jan 2007 08:00 EST http://goldbamboo.com/news-a215741.html Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to two of the company's investigational therapeutics. [click link for full article] Tue, 16 Jan 2007 08:00 EST http://goldbamboo.com/news-a219852.html ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced highly statistically significant results from its initial analysis of the Company's U.S. Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) once-daily formulation. The multi-center studies evaluated Xibrom once-daily formulation versus placebo in over 500 patients who underwent cataract surgery. [click link for full article] Fri, 09 Feb 2007 08:00 EST